anti-CRYM (CRYM) Antikörper

Human Crystallin, mu (CRYM) Interaktionspartner

1. Results suggest that mu-crystallin may play roles in development of cortical and hippocampal pyramidal cells in the early postnatal period, and in the later period, performs cell-specific functions in selected neuronal populations.

2. These findings confirm that, mechanistically, ketimine reductase/CRYM acts as a classical imine reductase and may explain the finding of bound pyruvate in the crystallized protein.

3. ketimine reductase is a key enzyme in the pipecolate pathway, which is the main lysine degradation pathway in the brain

4. The expression of mu-crystallin was regulated through the AP-1 site in the promoter.

5. Its ketimine reductase activity is strongly inhibited by thyroid hormones.

6. This protein has been found differentially expressed in thalami from patients with schizophrenia.

7. This is the first report linking hyperglycemia with thyroid hormone binding protein CRYM and suggests that the role of CRYM in diabetic complications should be further investigated.

8. Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues

9. up-regulation of mu-crystallin may play a specific and important role in pathogenesis of facioscapulohumeral muscular dystrophy

10. CRYM is a novel androgen-regulated gene whose expression is elevated in prostate cancer but down-regulated in castration therapy-resistant tumors.

11. Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia.

12. This protein has been found differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia.

Mouse (Murine) Crystallin, mu (CRYM) Interaktionspartner

1. The results demonstrated that Crym is a crucial regulator of muscle plasticity, controlling metabolic and contractile properties of myofibers, and thus the selective inactivation of Crym may be a potential therapeutic target for muscle-wasting diseases.

2. Reduction of Crym expression in Huntington's disease (HD) could render striatal neurons more susceptible to mutant huntingtin suggesting that Crym may be a key determinant of the vulnerability of the striatum.

3. CRYM expression increases and sustains the T3 responsiveness of genes in cells, especially with alteration of the pericellular T3 concentration.

4. Comparison of the apo and NADPH forms reveals a rearrangement of the protein upon NADPH binding that reduces the degrees of freedom of several residues and traps the conformation of the binding pocket in a more T3 competent state.

5. The expression of mu-crystallin was regulated through the AP-1 site in the promoter.

6. CRYM plays an important role in the development of the second peak of murine EIU.

7. Disruption of the CRYM gene decreases T(3) concentrations in tissues and serum without alteration of peripheral T(3) action in vivo.